Artera has improved its ArteraAI Prostate Test to support clinicians in determining the suitability of active surveillance for prostate cancer patients. This advancement enables more informed decisions regarding patient care.
The ArteraAI Prostate Test, powered by MMAI technology, evaluates a patient’s cancer progression risk and predicts treatment benefits. Its prognostic performance has been validated across diverse patient groups, including those undergoing active surveillance. The test result provides a prognostic risk assessment irrespective of treatment choice.
Artera CEO Andre Esteva emphasizes the test’s reliability and robustness, empowering healthcare providers to advance precision medicine. Through a partnership with PathNet, the test is now available to over 200 clinics.
The updated test report provides personalized guidance on active surveillance, facilitating discussions between clinicians and patients. It assesses the relative risk of cancer progression and compares it to patients undergoing active surveillance.
PathNet Co-owner Adam Cole notes that the test aligns with their commitment to pathology advancement. The partnership enables seamless integration of innovative technologies like Artera, benefiting a broader patient population.
Clinicians consider various factors when evaluating active surveillance for prostate cancer. The enhanced test report provides data on a patient’s relative risk of cancer aggressiveness, guiding decisions on active surveillance. By comparing the patient’s risk to others on active surveillance, the report assists in determining its appropriateness.
Artera continues to validate and refine its MMAI platform to provide better insights for cancer management.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
